石四药集团：非奈利酮已获国家药品监督管理局批准登记成为在上市制剂使用的原料药

Core Viewpoint - The announcement highlights that Shijiazhuang Pharmaceutical Group has received approval from the National Medical Products Administration of China for its active pharmaceutical ingredient, Fenofibrate, to be used in marketed formulations, making it the second domestic company to achieve this approval [1] Group 1 - Fenofibrate is primarily used for adult patients with chronic kidney disease associated with type 2 diabetes [1] - The drug can reduce the risk of a sustained decline in estimated glomerular filtration rate (eGFR), end-stage renal disease, cardiovascular death, and hospitalization due to heart failure [1]